Novartis' Entresto approved for heart failure

FDA approved Entresto sacubitril/ valsartan ( LCZ696) from Novartis AG (NYSE:NVS; SIX:NOVN) to reduce the risk of cardiovascular death and hospitalization for heart failure in chronic heart failure patients with reduced ejection fraction.

Novartis spokesperson Julie Masow told BioCentury the company would begin shipping the drug "very soon" at a wholesale acquisition cost (WAC) of $12.50 a day, less discounts. ...